Clinical Research Directory

Inclusion Criteria: 1.Subjects who understand and voluntarily sign the Informed Consent Form(ICF); 2.18-65years; 3.Clinical diagnosis of AML; 4.Accepted allogeneic blood stem cell transplantation within 60 to 28 days prior before initial infusion; 5.Complete donor chimerism and with high-risk recurrence factors prior to transplantation , or bone marrow examination shows positive MRD； 6.Have already recovered from the adverse reactions of previous treatment； 7.Having appropriate organ functions； 8.Eastern Cooperative Oncology Group(ECOG)\<3; 9.Subjects who are able to comply with contraceptives from the study period to 6 months after the end of this study; Exclusion Criteria: 1. Bone marrow examination shows hematological recurrence; 2. Have malignant tumors within 5 years before screening; 3. Subjects with acute promyelocytic leukemia(APL); 4. Subjects with severe respiratory diseases; 5. Subjects with clear history of neurological or psychiatric disorders in the past; 6. Active central nervous system involvement； 7. HIV(human immunodeficiency virus) antibody positive,treponema pallidum(TP) antibody positive.Have active hepatitis B or hepatitis C; 8. Allergies to NCR300 or its excipients; 9. Subjects with active cardiovascular and cerebrovascular diseases; 10. Received organ transplantation or planned transplantation； 11. Received other treatment drugs after transplantation； 12. Graft-Versus-Host Disease (GVHD)\>II grades; 13. Subjects with active nervous system autoimmune or inflammatory diseases; 14. Expected survival period within 3 months; 15. Have alcohol or drug addiction or with a clear history of mental disorders or with a history of drug abuse or drug use of psychotropic substances; 16. Having mental illness； 17. Having uncontrollable active infections; 18. Subjects whose state is not suitable for entering the study; 19. Other situations determined by investigator that it is not suitable to enter the study.